首页> 外国专利> Preparation and use of 2-methyl-4-dipropylamino-8(2',4'-dichlorophenyl)-quinoline and 2-methyl-4-(N-propyl-N-cyclopropanemethyl)amino-8(2',4'-dichlorophenyl)-quinoline for treating corticotropin-releasing factor related diseases

Preparation and use of 2-methyl-4-dipropylamino-8(2',4'-dichlorophenyl)-quinoline and 2-methyl-4-(N-propyl-N-cyclopropanemethyl)amino-8(2',4'-dichlorophenyl)-quinoline for treating corticotropin-releasing factor related diseases

机译:2-甲基-4-二丙基氨基-8(2',4'-二氯苯基)-喹啉和2-甲基-4-(N-丙基-N-环丙烷甲基)氨基-8(2',4'-二氯苯基)-喹啉治疗促肾上腺皮质激素释放因子相关疾病

摘要

A compound of the Formula (I) having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I). Wherein; X is N or CH; R1 is C1-6alkyl, NR6R7, OR7 or SR7; in case X is N then R2 is hydrogen, C1-6alkyl, C1-6alkyloxy or C1-6alkylthio; in case X is CH then R2 is C1-6alkyl, C1-6alkyloxy or C1-6alkylthio; R3 is Ar1 or Het1; R4 and R5 are each independently selected from hydrogen, halo, C1-6alkyl, C1-6alkyloxy, trifluoromethyl, cyano, nitro, amino, and mono- or di(C1-6alkyl)amino; R6 is hydrogen, C1-5alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl or C1-6alkyloxyC1-6alkyl; R7 is C1-5alkyl, mono- or di(C3-6cycloalkyl)methyl, Ar2CH2, C1-6alkyloxyC3-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, C1-6alkylthioC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, C1-6alkylcarbonylC1-6alkyl; or R6 and R7 taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C1-6alkyl or C1-6alkyloxyC1-6alkyl; and Ar1 is phenyl; phenyl substituted with 1,2 or 3 substituents each independently selected from halo, C1-6alkyl, trifluoromethyl, hydroxy, cyano, C1-6alkyloxy, benzyloxy, C1-6alkylthio, nitro, amino and mono- or di(C1-6alkyl)amino; Het1 is pyridinyl; pyridinyl substituted with 1,2 or 3 substituents each independently selected from halo, Cl-6alkyl, trifluoromethyl, hydroxy, cyano, C1-6alkyloxy, benzyloxy, C1-6alkylthio, nitro, amino, and mono- or di(C1-6alkyl)amino; and Ar2 is phenyl; phenyl substituted with 1,2 or 3 substituents each independently selected from halo, C1-6alkyl, C1-6alkyloxy, di(C1-6alkyl)aminoC1-6alkyl, trifluoromethyl.
机译:具有CRF受体拮抗特性的式(I)化合物;含有这类化合物作为活性成分的药物组合物;通过施用有效量的式(I)化合物来治疗与CRF过度分泌有关的疾病(例如抑郁症,焦虑症,药物滥用)的方法。其中X为N或CH; R1是C1-6烷基,NR6R7,OR7或SR7;如果X是N,则R 2是氢,C 1-6烷基,C 1-6烷氧基或C 1-6烷硫基;如果X是CH,则R 2是C 1-6烷基,C 1-6烷氧基或C 1-6烷硫基; R3是Ar1或Het1; R4和R5各自独立地选自氢,卤素,C1-6烷基,C1-6烷氧基,三氟甲基,氰基,硝基,氨基和单或二(C1-6烷基)氨基; R 6是氢,C 1-5烷基,单或二(C 3-6环烷基)甲基,C 3-6环烷基,C 3-6烯基,羟基C 1-6烷基,C 1-6烷基羰基氧基C 1-6烷基或C 1-6烷氧基C 1-6烷基; R7是C1-5烷基,单或二(C3-6环烷基)甲基,Ar2CH2,C1-6烷氧基C3-6烷基,羟基C1-6烷基,C3-6烯基,噻吩基甲基,呋喃基甲基,C1-6烷基硫代C1-6烷基,单或二(C1- 6烷基)氨基C 1-6烷基,二(C 1-6烷基)氨基,C 1-6烷基羰基C 1-6烷基;或者R6和R7与它们所连接的氮原子一起可以形成吡咯烷基,哌啶基,高哌啶基或吗啉基,任选地被C1-6烷基或C1-6烷氧基C1-6烷基取代; Ar 1为苯基;被1,2或3个取代基取代的苯基,所述取代基各自独立地选自卤素,C 1-6烷基,三氟甲基,羟基,氰基,C 1-6烷氧基,苄氧基,C 1-6烷硫基,硝基,氨基和单或二(C 1-6烷基)氨基; Het1是吡啶基;被1,2或3个取代基取代的吡啶基,各自独立地选自卤素,C1-6烷基,三氟甲基,羟基,氰基,C1-6烷氧基,苄氧基,C1-6烷硫基,硝基,氨基和单或二(C1-6烷基)氨基; Ar 2为苯基;被1,2或3个取代基取代的苯基,各自独立地选自卤素,C 1-6烷基,C 1-6烷氧基,二(C 1-6烷基)氨基C 1-6烷基,三氟甲基。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号